Study of DU-176b Aged 80 Years or Older
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 984 participants.
Also called NCT02801669
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose prevention
- Phase
- Phase 3
- Enrolled
- 984 participants
- Sponsor
- Registry
-
NCT02801669
-
- Other papers using this trial's data
- Effect of 15-mg Edoxaban on Clinical Outcomes in 3 Age Strata in Older Patients With Atrial Fibrillation: A Prespecified Subanalysis of the ELDERCARE-AF Randomized Clinical Trial
- Efficacy and Safety of Low-Dose Edoxaban by Body Weight in Very Elderly Patients With Atrial Fibrillation: A Subanalysis of the Randomized ELDERCARE-AF Trial
- Laboratory Test Predictors for Major Bleeding in Elderly (≥80 Years) Patients With Nonvalvular Atrial Fibrillation Treated With Edoxaban 15 mg: Sub-Analysis of the ELDERCARE-AF Trial
- Low-Dose Edoxaban in Very Elderly Patients with Atrial Fibrillation
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Japan
- Registry status
- Completed
Technical summary
Registry record NCT02801669. Randomized; triple masking; primary purpose prevention. Start 2016-08-05 (actual); primary completion 2019-12-27 (actual). Results posted on 2020-11-19.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study of DU-176b Aged 80 Years or Older
- Condition
- Atrial Fibrillation
- Intervention (Drug)
- Du-176b
- Intervention (Drug)
- placebo
- Lead sponsor
- Daiichi Sankyo Co., Ltd.
Record details
- Record id
cardio:ct-nct02801669- Content hash
cf8b7f7497931850c899c5e64f218fa589fa4aaf40fcccbbc02ca9bbffc4ce0b